Greeting from the President

Noriko Osumi

I was appointed President of the Japanese Society of Neuropsychopharmacology (JSNP) on November 14, 2020, succeeding Past President Dr. Kazuyuki Nakagome. I would like to offer a few words of greeting as I take charge of the JSNP for the next two years together with Vice President Prof. Nakao Iwata.

The JSNP was founded as a psychopharmacological society consisting of psychiatric clinicians and basic researchers, and this year marked the 50th anniversary of its founding. The 50th Annual Meeting, which I chaired, was held jointly with the 42nd Annual Meeting of the Japanese Society of Biological Psychiatry and the 4th Annual Meeting of the Japanese Society of Psychopharmacology. It was held online for the first time in order to comply with COVID-19. In addition, thanks to the efforts of the 50th Anniversary Project Working Group, the 50th anniversary commemorative book was published and a commemorative symposium was held.

In the midst of a declining birthrate, while many societies are struggling with declining membership, our society has seen a 1.5-fold increase in membership during the term of Past President Nakagome. It is believed that the society will soon reach 2,000 members. This can be regarded as proof that the psychiatric field is attracting attention in society. Among the various mental disorders, this year the media has repeatedly reported on the increase in gambling addiction, internet addiction, and suicide, especially among women and young people, due to the effects of the corona virus disaster. On a decadal basis, the rising incidence of neurodevelopmental disorders is also putting pressure on the educational field.

The mission of our society is to provide more appropriate drugs to improve the QOL of each patient. To do so, drug discovery based on an understanding of etiology and pathogenesis is essential. Since the time of former President Prof. Shigeto Yamawaki, the society has been promoting public private partnerships to advance the development of psychotropic drugs. This year, we will continue to develop technology for stratification of psychiatric disorders and create a basic database of registered cases for clinical trials. In addition, we would like to contribute to the development of new drugs by introducing appropriate personnel from among our members in response to consultations from companies.

Also, academic societies are important as an interface between professionals and citizens. The JSNP has already edited "Guidelines for the Pharmacological Treatment of Schizophrenia," published by Igaku Shoin, and has been engaged in activities to disseminate, educate, and verify these guidelines. We will also publish similar guidelines for other psychiatric disorders in the future.

The Society has also been active in internationalization. JSNP members actively participate as board members of the International College of Neuropsychopharmacology (CINP), and members of the European College of Neuropsychopharmacology (ECNP), the American College of Neuropsychopharmacology (ACNP), etc. Former President Dr. Kazutaka Ikeda currently serves as President of the Asian College of Neuropsychopharmacology (AsCNP) and has successfully invited the 2024 CINP Congress to Tokyo. The Asian regions are expected to gain more weight in the world in the future, and I hope that we can maintain good friendly relations.

We had been publishing the Japanese Journal of Neuropsychopharmacology as our official journal. In 2018, it has been transformed into Neuropsychopharmacology Reports (NPPR) as an online journal from Wiley. Thanks to the efforts of Editor-in-Chief Dr. Tsuyoshi Miyakawa, the journal will be able to publish original papers, case reports, and review articles with prompt peer review. We encourage all members to submit and cite their papers to NPPR.

I will do my best to make sure that the new half-century of our society will start smoothly. I look forward to working with you all.

November 2020
President of The Japanese Society of Neuropsychopharmacology
Noriko Osumi